Psychopharmacology

, Volume 196, Issue 4, pp 511–520

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis

Review

Abstract

Rationale

A number of reviews have claimed that the selective serotonin and noradrenalin re-uptake inhibitor venlafaxine is more effective than selective serotonin re-uptake inhibitors (SSRIs) in achieving remission and symptom reduction in major depression.

Objectives

The aim of this study was to systematically review studies on the efficacy of venlafaxine vs SSRI and to evaluate the influence of methodological issues on the effect sizes.

Materials and methods

Following a systematic literature search, we pooled data on depression scores, response, remission and dropout rates. We also performed sub-group analyses.

Results

Seventeen studies were included. We found no significant superiority in remission rates (risk ratio [RR] = 1.07, 95% confidence intervals [95%CI] = 0.99 to 1.15, numbers needed to treat [NNT] = 34) and a small superiority in response rates (RR = 1.06, 95%CI = 1.01 to 1.12, NNT = 27) over SSRIs. There was a small advantage to venlafaxine in change scores (effect size = −0.09, 95%CI = −0.16 to −0.02, p = 0.013), which did not reach significance when post-treatment scores were used (effect size = −0.06, 95%CI = −0.13 to 0.00). Discontinuation rates due to adverse events were 45% higher in the venlafaxine group. The main reasons for the differences between this analysis and previous reviews were the exclusion of studies with methodological limitations, avoiding to pool selectively reported study results and exclusion of studies available as abstracts only.

Conclusions

Our analysis does not support a clinically significant superiority of venlafaxine over SSRIs. Differences between our study and previous reviews were not accounted for by technical aspects of data synthesis, but rather by study selection and choice of outcome parameters.

Keywords

Venlafaxine Anti-depressant Meta-analysis Systematic review 

Supplementary material

213_2007_975_MOESM1_ESM.doc (180 kb)
Electronic supplementary material(DOC 179 kb)

References

  1. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J (2004) Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19:1123–1130PubMedCrossRefGoogle Scholar
  2. Alves C, Cachola I, Brandao J (1999) Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Companion J Clin Psychiatry 5:57–63Google Scholar
  3. American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157:1–45Google Scholar
  4. Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57:161–178PubMedCrossRefGoogle Scholar
  5. Ballus C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutierrez M, Casais L, Riesgo Y (2000) The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 15:43–48PubMedGoogle Scholar
  6. Barbui C, Cipriani A, Brambilla P, Hotopf M (2004) “Wish bias” in antidepressant drug trials? J Clin Psychopharmacol 24:126–130PubMedCrossRefGoogle Scholar
  7. Bielski RJ, Ventura D, Chang CC (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65:1190–1196PubMedCrossRefGoogle Scholar
  8. Borenstein M, Hedges L, Higgins J, Rothstein H (2005) Comprehensive meta-analysis, version 2. Biostat, Englewood, NJGoogle Scholar
  9. Cipriani A, Geddes J, Barbui C (2007) Venlafaxine for major depression. More evidence that risks outweigh benefits for most patients? BMJ 334:215–216PubMedCrossRefGoogle Scholar
  10. Clerc GE, Ruimy P, Verdeau-Pailles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9:139–143PubMedCrossRefGoogle Scholar
  11. Costa e Silva J (1998) Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59:352–357PubMedGoogle Scholar
  12. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison clomipramine: a controlled multicenter study. Psychopharmacology 90:131–138CrossRefGoogle Scholar
  13. Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18:289–299CrossRefGoogle Scholar
  14. Dierick M, Ravizza L, Realini R, Martin A (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 20:57–71PubMedCrossRefGoogle Scholar
  15. Egger M, Smith GD, Altman DG (2001) Systematic reviews in health care: meta-analysis in context. BMJ Books, LondonGoogle Scholar
  16. Einarson TR, Arikian, SR, Casciano J (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21:296–308PubMedCrossRefGoogle Scholar
  17. Fochtman LJ, Gelenberg A, Fochtman LJ (2006) Guideline watch: practice guideline for the treatment of patients with major depressive disorder, 2nd edition. Available at: http://www.psych.org/psych_pract/treatg/pg/MDD.watch.pdf. Accessed October 6, 2006
  18. Frank E, Prien RF, Jarrett RB (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855PubMedGoogle Scholar
  19. Freemantle N, Calvert M (2007) Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol 60:658–659CrossRefGoogle Scholar
  20. Furukawa TA, Barbui C, Cipriani A, Bambilla P, Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59:7–10PubMedCrossRefGoogle Scholar
  21. Geddes JR, Freemantle N, Mason J (2006) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (Cochrane Review). In: The Cochrane Library, Issue 3, 2006. Update Software, OxfordGoogle Scholar
  22. Geerts S, Lacante P, Mignon A (1999) Venlafaxine versus fluoxetine in the treatment of depressed patients with concomitant anxiety. Eur Neuropsychopharmacol 9:S224CrossRefGoogle Scholar
  23. Hansen RA, Gartlehner G, Lohr KN (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415–426PubMedGoogle Scholar
  24. Higgins JPT, Thompson SG, Deeks JJ (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  25. Jorgensen AW, Hilden J, Gotzsche PC (2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333:782PubMedCrossRefGoogle Scholar
  26. Kavirajan H (2004) Venlafaxine and SSRI remission data revisited. Br J Psychiatry 184:452–453PubMedCrossRefGoogle Scholar
  27. Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152–3160PubMedCrossRefGoogle Scholar
  28. Kennedy SH, Andersen HF, Lam RW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122–131PubMedGoogle Scholar
  29. Kessler RC, Demler O, Frank RG (2005) Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515–2523PubMedCrossRefGoogle Scholar
  30. Khan A, Leventhal RM, Khan SR, Brown WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40–45PubMedCrossRefGoogle Scholar
  31. Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB (2005) Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 30:445–460PubMedCrossRefGoogle Scholar
  32. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326:1014PubMedCrossRefGoogle Scholar
  33. Machado M, Iskedjian M, Riuz I, Einarson TR (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 22:1825–1837PubMedCrossRefGoogle Scholar
  34. McPartlin GM, Reynolds A, Anderson C, Casoy J (1998) A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Companion J Clin Psychiatry 4:127–132Google Scholar
  35. Mehtonen O-P, Sogaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61:95–100PubMedCrossRefGoogle Scholar
  36. Moher D, Jones A, Cook DJ (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis? Lancet 352:609–613PubMedCrossRefGoogle Scholar
  37. Moja LP, Telaro E, D’Amico R (2005) Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality cross sectional study. BMJ 330:1053PubMedCrossRefGoogle Scholar
  38. Montgomery SA, Huusom AKT, Bothmer J (2004) A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57–64PubMedCrossRefGoogle Scholar
  39. National Institute for Health and Clinical Excellence (2004) Management of depression in primary and secondary care. National Clinical Practice Guideline Number 23. Available at: http://www.nice.org.uk/CG023NICEguideline. Accessed October 13, 2006
  40. Nemeroff CB, Thase ME (2007) A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41:351–359PubMedCrossRefGoogle Scholar
  41. Paykel ES (2002) Achieving gains beyond response. Acta Psychiatr Scand Suppl 106:12–17CrossRefGoogle Scholar
  42. Roose SP, Schatzberg AF (2005) The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol 25:S1–S7PubMedCrossRefGoogle Scholar
  43. Rudolph RL (2002) Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 106:24–30CrossRefGoogle Scholar
  44. Rudolph RL, Feiger AD (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:171–181PubMedCrossRefGoogle Scholar
  45. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998) A randomized, placebo-controlled, dose–response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116–122PubMedGoogle Scholar
  46. Salinas E, Venlafaxine-XR-Study-Group (1997) Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 42(Suppl I):297SGoogle Scholar
  47. Schatzberg A, Roose S (2006) A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14:361–370PubMedCrossRefGoogle Scholar
  48. Shelton C, Entsuah R, Padmanabhan SK (2005) Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 20:233–238PubMedCrossRefGoogle Scholar
  49. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, Lydiard RB, Zajecka JM, Dunner DL (2006) Randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 67:1674–1681PubMedCrossRefGoogle Scholar
  50. Silverstone PH, Ravindran A (1999) Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 60:22–28PubMedCrossRefGoogle Scholar
  51. Sir A, D’Souza RF, Uguz S, George T, Vahip S, Hopwood M (2005) Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66:1312–1320PubMedGoogle Scholar
  52. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180:396–404PubMedCrossRefGoogle Scholar
  53. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT (2000) Multiple recurrences of major depressive disorder. Am J Psychiatry 157:229–233PubMedCrossRefGoogle Scholar
  54. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234–241PubMedCrossRefGoogle Scholar
  55. Thiessen Philbrooke H, Barrowman N, Garg AX (2007) Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation. J Clin Epidemiol 60:228–240CrossRefGoogle Scholar
  56. Tylee A, Beaumont G, Bowden MW, Reynolds A (1997) A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Companion J Clin Psychiatry 3:51–58Google Scholar
  57. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F (2000) Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 15:29–34PubMedCrossRefGoogle Scholar
  58. Zanardi R, Franchini L, Serretti A (2000) Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 61:26–29PubMedCrossRefGoogle Scholar
  59. Zimmerman M, Posternak MA, Chelminski I (2005) Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis 193:170–175PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.University of UlmUlmGermany

Personalised recommendations